What Neurocrine Biosciences, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 4 | 39 |
| Total trades | 30 | 197 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 61,432 | 794,024 |
| Disposed | 41,022 | 678,639 |
| Net activity | +20,410 | +115,385 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Abernethy Matt | Chief Financial Officer | Sep 14 | Open-market sale · S | −2,311 | $157.20 | −$363K | 42,808 |
| Boyer David W. | Chief Corp. Affairs Officer | Sep 14 | Open-market sale · S | −826 | $157.45 | −$130K | 8,722 |
| Gorman Kevin Charles | Director | Sep 11 | Withheld — tax / exercise cost · F | −7,839 | $156.22 | −$1.22M | 517,797 |
| Gorman Kevin Charles | Director | Sep 11 | Grant / award · A | +14,343 | — | — | 525,636 |
| Abernethy Matt | Chief Financial Officer | Sep 11 | Withheld — tax / exercise cost · F | −2,709 | $156.22 | −$423K | 45,119 |
| Abernethy Matt | Chief Financial Officer | Sep 11 | Grant / award · A | +5,020 | — | — | 47,828 |
| Cooke Julie | Chief Human Resources Officer | Sep 11 | Withheld — tax / exercise cost · F | −1,936 | $156.22 | −$302K | 24,025 |
| Cooke Julie | Chief Human Resources Officer | Sep 11 | Grant / award · A | +3,587 | — | — | 25,961 |
| Gano Kyle | Chief Executive Officer | Sep 11 | Withheld — tax / exercise cost · F | −994 | $156.22 | −$155K | 154,728 |
| Gano Kyle | Chief Executive Officer | Sep 11 | Grant / award · A | +1,842 | — | — | 155,722 |
| Gano Kyle | Chief Executive Officer | Sep 11 | Withheld — tax / exercise cost · F | −3,386 | $156.22 | −$529K | 153,880 |
| Gano Kyle | Chief Executive Officer | Sep 11 | Grant / award · A | +6,275 | — | — | 157,266 |
| Lippoldt Darin | Chief Legal Officer | Sep 11 | Withheld — tax / exercise cost · F | −2,419 | $156.22 | −$378K | 56,793 |
| Lippoldt Darin | Chief Legal Officer | Sep 11 | Grant / award · A | +4,483 | — | — | 59,212 |
| Onyia Jude | Chief Scientific Officer | Sep 11 | Withheld — tax / exercise cost · F | −1,936 | $156.22 | −$302K | 22,647 |
| Onyia Jude | Chief Scientific Officer | Sep 11 | Grant / award · A | +3,587 | — | — | 24,583 |
| Boyer David W. | Chief Corp. Affairs Officer | Sep 11 | Withheld — tax / exercise cost · F | −1,936 | $156.22 | −$302K | 9,548 |
| Boyer David W. | Chief Corp. Affairs Officer | Sep 11 | Grant / award · A | +3,587 | — | — | 11,484 |
| Benevich Eric | Chief Commercial Officer | Sep 11 | Withheld — tax / exercise cost · F | −3,386 | $156.22 | −$529K | 67,297 |
| Benevich Eric | Chief Commercial Officer | Sep 11 | Grant / award · A | +6,275 | — | — | 70,683 |
Loading...
